Treatment of schizophrenia and moderate to severe manic episodes associated with bipolar disorder. It may also be used for prevention of recurrence in appropriately selected patients with bipolar disorder who have responded to olanzapine.
Adult: The usual oral dose depends on the indication and clinical condition.
For schizophrenia, treatment is commonly initiated at 5–10 mg once daily.
For manic episodes, commonly used starting doses are 10–15 mg once daily, depending on whether olanzapine is used alone or in combination therapy.
Dose adjustment should be individualized according to clinical response and tolerability.
Each tablet contains:
Olanzapine ........ 5mg
Olanzapine is an atypical antipsychotic agent with activity at multiple neurotransmitter receptors, particularly serotonin and dopamine receptors.
Olanzapine exhibits antagonistic activity at serotonin 5-HT₂ and dopamine D₂ receptors, together with activity at several other serotonergic, dopaminergic, muscarinic, adrenergic and histaminergic receptors.
Its antipsychotic activity is believed to be mediated primarily through antagonism of dopamine and serotonin receptors.
Olanzapine is well absorbed after oral administration. Peak plasma concentrations generally occur within several hours.
It is extensively metabolized in the liver, primarily through glucuronidation and oxidative metabolism. Its elimination half-life varies considerably between individuals.
Contraindicated in patients with known hypersensitivity to olanzapine. Additional contraindications may apply according to local approved labeling.
Patients should be monitored for weight gain, hyperglycaemia, dyslipidaemia and other metabolic changes.
Use caution in patients with cardiovascular disease, seizure disorders, hepatic impairment, or conditions predisposing to hypotension.
Olanzapine is not approved for treatment of dementia-related psychosis in elderly patients in many regulatory jurisdictions.
Common adverse effects include somnolence, weight gain, increased appetite, dizziness, orthostatic hypotension and metabolic abnormalities.
Extrapyramidal symptoms may occur, although generally less frequently than with many conventional antipsychotics.
Overdose may produce tachycardia, agitation, altered consciousness, dysarthria and extrapyramidal symptoms. Severe poisoning may result in respiratory depression, hypotension, arrhythmias and coma.
Treatment is supportive with appropriate monitoring.
CNS depressants may enhance sedation. Medicines affecting CYP1A2 activity may alter olanzapine concentrations. Smoking can also affect olanzapine metabolism through CYP1A2 induction.
Store below 30*C in cool and dry place. Protect from light and moisture. Keep out or reach and sight of children
10 x 10’s Alu-Alu Blister.